Skip to main content
Premium Trial:

Request an Annual Quote

Unigen to Use Omics Tools to Discover Potential Therapeutics in Atlantic Ocean Microbes

NEW YORK (GenomeWeb News) - Unigen Pharmaceuticals and the University of Prince Edward Island will work together to study marine microorganisms from the Atlantic Ocean with the hopes of making discoveries that may lead to new therapeutics and commercial products, Unigen said late last week.
 
The marine collection research will be led by Russell Kerr, Canada Research Chair in Marine Natural Products at UPEI, who has been collecting samples from tropical Atlantic waters for two decades.
 
Unigen will extract the microbes from the samples and fractionate them using a high-throughput purification system, and will test these fractions on "biochemical, genomic, proteomic, in vitro, in vivo, and ex vivo models," the company said.
 
The company said active ingredients will be "separated and identified as leads for the development of pharmaceutical, nutraceutical, cosmoceutical, and functional food products."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.